The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture
Open accessAbstract
The transthyretin (TTR) amyloidoses are human diseases in which the misfolded TTR protein aggregates in tissues with subsequent visceral, peripheral, and autonomic nerve dysfunction. Recent reports have stressed the importance of oligomeric intermediates as major cytotoxic species in various forms of amyloidogenesis. We have examined the cytotoxic effects of several quaternary structural states of wild-type and variant TTR proteins on cells of neural lineage. TTR amyloid fibrils and soluble aggregates >100 kDa were not toxic. Incubation of TTR under the conditions of the cell assay and analysis by size-exclusion chromatography and SDS/PAGE reveal that monomeric TTR or relatively small, rapidly formed aggregates of a maximum size of six subunits were the major cytotoxic species. Small molecules that stabilize the native tetrameric state were shown to prevent toxicity. The studies are consistent with a model in which the misfolded TTR monomer rapidly aggregates to form transient low molecular mass assemblies (<100 kDa) that are highly cytotoxic in tissue culture.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Molecular Mechanisms of Amyloidosis
Merlini, G., & Bellotti, V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023144 · Cited by 1,920
The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways
Kelly, J. W. (1998) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(98)80016-x · Cited by 1,001
Self-citationVariant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans
Jacobson, D. R., Pastore, R. D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F. S., & Buxbaum, J. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702133360703 · Cited by 554
Self-citationPrevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics
Hammarström, P., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2003) · Science · doi:10.1126/science.1079589 · Cited by 525
Self-citationRational design of potent human transthyretin amyloid disease inhibitors.
Sacchettini, J. C., Klabunde, T., Petrassi, H. M., Oza, V. B., Raman, P., & Kelly, J. W. (2000) · Nature Structural Biology · doi:10.1038/74082 · Cited by 379
Self-citationSequence-dependent denaturation energetics: A major determinant in amyloid disease diversity
Hammarström, P., Jiang, X., Hurshman, A. R., Powers, E. T., & Kelly, J. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202495199 · Cited by 359
Self-citationDeposition of Transthyretin in Early Stages of Familial Amyloidotic Polyneuropathy
Mendes Sousa, M., Cardoso, I., Fernandes, R., Guimarães, A., & Saraiva, M. J. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63050-7 · Cited by 344
Quintas, A., Vaz, D. C., Cardoso, I., Saraiva, M. J. M., & Brito, R. M. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101024200 · Cited by 342
Therapeutic strategies for human amyloid diseases
Sacchettini, J. C., & Kelly, J. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd769 · Cited by 261
Self-citationAn Engineered Transthyretin Monomer that Is Nonamyloidogenic, Unless It Is Partially Denatured
Jiang, X., Smith, C. S., Petrassi, H. M., Hammarström, P., White, J. T., Sacchettini, J. C., & Kelly, J. W. (2001) · Biochemistry · doi:10.1021/bi011194d · Cited by 239
Self-citationLashuel, H. A., Wurth, C., Woo, L., & Kelly, J. W. (1999) · Biochemistry · doi:10.1021/bi991021c · Cited by 176
Self-citationThe Genetics of the Amyloidoses
Buxbaum, J. N., & Tagoe, C. E. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.543 · Cited by 154
Self-citationOnly amyloidogenic intermediates of transthyretin induce apoptosis
Andersson, K., Olofsson, A., Nielsen, E. H., Svehag, S., & Lundgren, E. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00465-5 · Cited by 118
Cardoso, I., Goldsbury, C. S., Müller, S. A., et al. (2002) · Journal of Molecular Biology · doi:10.1006/jmbi.2002.5441 · Cited by 118
Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases?
Buxbaum, J. N. (2003) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.09.009 · Cited by 88
Self-citationDamas, A. M., & Saraiva, M. J. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4273 · Cited by 86
White, J. T., & Kelly, J. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241406698 · Cited by 86
Self-citationSynthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors
Oza, V. B., Petrassi, H. M., Purkey, H. E., & Kelly, J. W. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00696-9 · Cited by 78
Self-citationHammarström, P., Jiang, X., Deechongkit, S., et al. (2001) · Biochemistry · doi:10.1021/bi010673+ · Cited by 75
Self-citationSpontaneous Aggregation and Cytotoxicity of the β-Amyloid Aβ1–40: A Kinetic Model
Taylor, B. M., Sarver, R. W., Fici, G. J., Poorman, R. A., Lutzke, B. S., Molinari, A., Kawabe, T. T., Kappenman, K., Buhl, A. E., & Epps, D. E. V. (2003) · Journal of Protein Chemistry · doi:10.1023/a:1023063626770 · Cited by 58
Characterization of intracellular amyloid fibrils in the human choroid plexus epithelial cells
Eriksson, L. G., & Westermark, P. (1990) · Acta Neuropathologica · doi:10.1007/bf00307626 · Cited by 22
Cited by
Protein Misfolding, Functional Amyloid, and Human Disease
Chiti, F., & Dobson, C. M. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.123901 · Cited by 6,423
A new era for understanding amyloid structures and disease
Iadanza, M. G., Jackson, M. P., Hewitt, E. W., Ranson, N. A., & Radford, S. E. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0060-8 · Cited by 980
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
Bulawa, C. E., Connelly, S., DeVit, M., Wang, L., Weigel, C., Fleming, J. A., Packman, J., Powers, E. T., Wiseman, R. L., Foss, T. R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121005109 · Cited by 742
Self-citationAmyloidosis: Pathogenesis and New Therapeutic Options
Merlini, G., Seldin, D. C., & Gertz, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2271 · Cited by 509
Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?
Lashuel, H. A., & Lansbury, P. T. (2006) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583506004422 · Cited by 400
Metadata
- Authors
- Reixach, N., Deechongkit, S., Jiang, X., Kelly, J. W., & Buxbaum, J. N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-02-23
- Volume
- 101
- Issue
- 9
- Pages
- 2817-2822
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2161532460
- Cited by
- 392
- References
- 22
- FWCI
- 7.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.